Methylprednisolone 1000 mg powder and solvent for solution for injection/infusion

DRUG2 trials

Sponsors

Rheacell GmbH & Co. KG, Kite Pharma Inc.

Conditions

Recessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctional Epidermolysis Bullosa (JEB)Relapsed/Refractory Mantle Cell Lymphoma

Phase 2

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)

CompletedCTIS2023-506641-35-00

Kite Pharma Inc.Relapsed/Refractory Mantle Cell Lymphoma

Start: 2018-07-09End: 2025-06-17Target: 68Updated: 2025-03-10

Phase 3

A double-blind, randomized, placebo-controlled, interventional, multicenter, phase III clinical trial to investigate the safety and efficacy of ABCB5-positive mesenchymal stromal cells (ABCB5+ MSCs) on epidermolysis bullosa (EB)

RecruitingCTIS2022-500266-10-00

Rheacell GmbH & Co. KGRecessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctional Epidermolysis Bullosa (JEB)

Start: 2023-06-13Target: 119Updated: 2025-12-02